IC-OS Weekly Webinar - How to use cardiac hematolologic biomarkers during the treatment of lymphoma and leukemia

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Dr. Matasar is an Associate Member of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, where he serves as the Section Head for aggressive B-cell lymphoma, as the Medical Director for the multi-disciplinary treatment center in Montvale, NJ, leads the Lymphoma Survivorship Clinic, and serves on the Center’s Research Council and Department of Medicine Executive Council. His research interests include clinical trials developing novel immunotherapies and targeted therapies to improve outcomes in B-cell lymphoma, quality and cost of care, and lymphoma survivorship.

Dr Ganatra serves as a Director of the Cardio-Oncology Program and Co-Director of the Cardiac MRI Program for Lahey Hospital and Medical Center, Beth Israel Lahey Health in Boston. His primary research interest is outcomes research in cardio-oncology. He serves on the Research and Scientific Committee of the International Cardio-Oncology Society (ICOS), the American College of Cardiology Cardio-Oncology leadership council, and on the editorial board of JACC Cardio-Oncology.

Teresa López-Fernández is a clinical investigator and consultant cardiologist at La Paz University Hospital in Madrid, Spain. She is specializes in cardiac imaging (she is board certified in advanced and transesophageal echocardiography by the European Society of Cardiology (ESC)) and cardio-oncology (she is board certified by the International Cardio-Oncology Society), and currently coordinates the cardio-oncology team at La Paz University Hospital. She is the founder and chair of the Spanish Cardio-Oncology Working Group at the Spanish Society of Cardiology (SEC) and the Secretary of the ESC Council of Cardio-Oncology.